Mark Cuban Cost Plus Drug Co. considered selling insulin but found the price doubled with shipping costs, CEO and co-founder Alex Oshmyansky, MD, PhD, said June 13 at the AHIP conference. 

Connecticut Gov. Ned Lamont signed a bill June 13 allowing pharmacists to prescribe birth control without a patient being required to visit a physician. 

Amid a shortage of amoxicillin and penicillin — the two main antibiotics for strep infections, which rose in early 2023 — Pfizer said it has "limited supply and [an] impending stock out situation" for some of its penicillin prefilled syringe…

Sanofi announced its latest endeavor into AI technologies with the use of an internal app, which company CEO Paul Hudson says is a move to align with its aim to become the "first pharma company powered by artificial intelligence at…

The FDA approved Ironwood Pharmaceuticals' Linzess (linaclotide) capsules June 12, making it the first pediatric treatment for functional constipation. 

An over-the-counter topical treatment for men with erectile dysfunction on May 12 was authorized by the FDA for marketing. Futura Medical's Eroxon gel can now be marketed as a de novo medical device.

Novo Nordisk's Type 2 diabetes drug Ozempic (semaglutide) shot up in popularity for its off-label use for weight loss. Here are six recent updates on the drug: 

The Alliance for Patient Access, a national advocacy group, has published a report outlining key ways employer-sponsored health plans can benefit from alternative funding programs at the expense of some patients.

Novartis announced June 12 that it will acquire Chinook Therapeutics, a Seattle-based biopharmaceutical company that develops novel kidney medicines, for a total value of $3.5 billion.

Francis deSouza, CEO of San Diego-based biotech company Illumina, stepped down from the role June 11 and will be an adviser through July.